Adebrelimab is a monoclonal antibody that targets the PD-L1 protein, playing a critical role in cancer immunotherapy. By blocking the interaction between PD-L1 and its receptor PD-1 on T cells, it helps restore the immune system’s ability to recognize and destroy cancer cells. It is primarily used in the treatment of various solid tumors, including non-small cell lung cancer, gastric cancer, and hepatocellular carcinoma. Adebrelimab is often administered in combination with other anticancer therapies to enhance treatment efficacy. Its use is particularly beneficial in patients whose tumors express high levels of PD-L1, enabling a more targeted and effective immune response.